EUVIMEDEUVIMED entdecken
Crossref

Distinctive epidemiology and prognosis of de novo and secondary cutaneous angiosarcoma patients

Junsen Ye, Wei Han, Jin Xu

International Journal of Dermatology · 2023

DOI: 10.1111/ijd.16673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2023. Verfasst von Junsen Ye und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Scientific Education, The First People's Hospital of Jiande, Jiande, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Hemangiosarcoma, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous angiosarcoma (cAS) is a rare and not well‐established malignant neoplasm characterized by dismal prognosis. Treatment for cAS remains controversial.

Objective

From 1975 to 2016, a total of 872 patients with cAS (379 secondary cAS [s‐cAS] patients and 493 de novo cAS [dn‐cAS]) patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database.

Methods

Survival analyses were performed utilizing Kaplan‐Meier curves and Cox proportional hazards regression models.

Results

Both the number of s‐cAS patients and dn‐cAS patients climbed steadily over 42 years. There is a gradual increase in the proportion of s‐cAS among whole cAS patients for each interval, ranging from 0% to 51.2%.Taking into account a combination of Kaplan‐Meier and Cox regression methods, the survival of s‐cAS is similar to dn‐cAS. On multivariate analysis, older age, greater tumor size, primary site located at lower extremity, advanced stage, and no surgery were independent prognostic factors of decreased overall survival (OS) in both the s‐cAS and dn‐cAS groups.

Conclusion

Apparent increase in the number of s‐cAS patients requires further attention. Surgery is still recommended for the treatment of both s‐cAS and dn‐cAS patients, and the requirement for treatment improvement is imperative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemangiosarcomaSkin NeoplasmsHumansSEER ProgramRetrospective StudiesSurvival RatePrognosisProportional Hazards ModelsKaplan-Meier EstimateNeoplasm Staging

Autor:innen und Institutionen

  • The Department of Scientific Education, The First People's Hospital of Jiande, Jiande, Hangzhou, Zhejiang, China.
  • Institute of Regenerative Biology and Medicine, Helmholtz Center Munich, Munich, Germany.

Zitieren

APA

Ye, J., Han, W., & Xu, J. (2023). Distinctive epidemiology and prognosis of de novo and secondary cutaneous angiosarcoma patients. International Journal of Dermatology. https://doi.org/10.1111/ijd.16673

Vancouver

Ye J, Han W, Xu J. Distinctive epidemiology and prognosis of de novo and secondary cutaneous angiosarcoma patients. International Journal of Dermatology. 2023. doi:10.1111/ijd.16673

BibTeX
@article{Ye2023,
  author = {Ye, Junsen and Han, Wei and Xu, Jin},
  title = {Distinctive epidemiology and prognosis of de novo and secondary cutaneous angiosarcoma patients},
  journal = {International Journal of Dermatology},
  year = {2023},
  doi = {10.1111/ijd.16673}
}
Kostenlos starten →